Clinical Trial Update: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tolerization to reduce intolerance to pegloticase and prolong urate-lowering effect in gout.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• Pegloticase (pegloticase)

Snippet

Sponsor: Ampel BioSolutions, LLC | Conditions: Gout | Phase 2 | Status: COMPLETED